1. Harnessing the Immunotherapy Revolution for the Treatment of Childhood Cancers 
Robbie G. Majzner, Sabine Heitzeneder, Crystal L. Mackall 
Cancer Cell 
Volume 31, Issue 4, Pages (April 2017)
DOI: /j.ccell
Copyright © 2017 Elsevier Inc. Terms and Conditions

2. Figure 1 Categories of Cancer Immunotherapeutics
Cancer immunotherapies can be categorized according to whether they amplify existing immune responses mediated by natural immune effectors, versus synthetic immunotherapies, which create non-natural immune effectors that initiate new immune responses.
Cancer Cell  , DOI: ( /j.ccell )
Copyright © 2017 Elsevier Inc. Terms and Conditions

3. Figure 2
Antigenic Milieu of Sporadic Pediatric Cancers, Sporadic Adult Cancers, and bMMRD Pediatric Cancers
A word cloud is used to illustrate the basis upon which sporadic pediatric cancers demonstrate lower immunogenicity compared with adult sporadic cancers and cancers found in children with biallelic mismatch repair deficiency (bMMRD). Antigen categories include those derived from nonsynonymous somatic mutations (NSSMs), viral antigens, cancer testis antigens, tissue differentiation antigens, and oncofetal antigens. The word size is proportion to the immunogenicity of a particular antigen, and the number of repeats of a specific antigen class is proportional to the frequency of that class of antigen within the tumor type shown.
Cancer Cell  , DOI: ( /j.ccell )
Copyright © 2017 Elsevier Inc. Terms and Conditions

4. Figure 3 Antigen Escape after Treatment with CD19-CAR T Cells
Isoform switch and lineage switch represent distinct mechanisms by which CD19 loss is induced. Isoform switch refers to the most common pathways, wherein leukemic blasts expressing variant isoforms of CD19 that lack the epitopes recognized by the CAR and/or are preferentially retained intracellularly are selected. Lineage switch refers to the development of a myeloid-like leukemia that does not express CD19 in response to pressure exerted via the CD19-CAR. Arrow widths illustrate the substantially increased frequency of isoform switch compared with lineage switch following CD19-CAR therapy.
Cancer Cell  , DOI: ( /j.ccell )
Copyright © 2017 Elsevier Inc. Terms and Conditions

5. Figure 4 Targeting Multiple Antigens Using CAR T Cells
Multispecificity can be achieved by co-administering two different T cell products with each expressing a different CAR (top), expressing two different CAR molecules on one T cell with a bicistronic vector or by cotransducing T cells with two different viruses (middle), or creating a single CAR molecule that can target multiple antigens (bottom).
Cancer Cell  , DOI: ( /j.ccell )
Copyright © 2017 Elsevier Inc. Terms and Conditions